Andreas Pinter

List of Publications by Year
in descending order

41 papers	2,046 citations	471509 17 h-index	289244 40 g-index
42 all docs	42 docs citations	42 times ranked	2069 citing authors

#	Article	IF	Citations
1	Direct comparison of risankizumab and fumaric acid esters in systemic therapyâ€“naÃ¯ve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. British Journal of Dermatology, 2022, 186, 30-39.	1.5	9
2	A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 228-236.	2.4	21
3	Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*. British Journal of Dermatology, 2022, 186, 942-954.	1.5	22
4	Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatology and Therapy, 2022, 12, 561-575.	3.0	7
5	Mechanism of antiâ€inflammatory effects of rifampicin in an ex vivo culture system of hidradenitis suppurativa. Experimental Dermatology, 2022, 31, 1005-1013.	2.9	8
6	Longâ€term, durable, absolute Psoriasis Area and Severity Index and healthâ€related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderateâ€toâ€severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 855-865.	2.4	11
7	Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis. JAMA Dermatology, 2022, 158, 533.	4.1	17
8	Low Pneumococcal Vaccination among Patients with Psoriasis in Germany: Results from Vac-Pso. Vaccines, 2022, 10, 1005.	4.4	0
9	Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (<scp>PSoHO</scp>). Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2087-2100.	2.4	15
10	Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker â€“ a retrospective multicenter study. Journal of Dermatological Treatment, 2021, 32, 878-882.	2.2	24
11	Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderateâ€toâ€severe plaque psoriasis naÃ¯ve to systemic treatment. British Journal of Dermatology, 2021, 184, 548-550.	1.5	4
12	A headâ€toâ€head comparison of ixekizumab vs. guselkumab in patients with moderateâ€toâ€severe plaque psoriasis: 24â€week efficacy and safety results from a randomized, doubleâ€blinded trial*. British Journal of Dermatology, 2021, 184, 1047-1058.	1.5	58
13	A phase 4, randomized, headâ€toâ€head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderateâ€toâ€severe plaque psoriasis (CHANGE). Journal of the European Academy of Dermatology and Venereology, 2021, 35, 701-711.	2.4	13
14	mTORC1 â€“ a potential player in the pathogenesis of hidradenitis suppurativa?. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e444-e447.	2.4	7
15	Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASIÂâ‰¥Â16) analysis of randomized phase 2B study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1562-1568.	2.4	33
16	Patientâ€reported outcomes with risankizumab versus fumaric acid esters in systemic therapyâ€naÃ¯ve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1686-1691.	2.4	12
17	Biologic Treatment in Combination with Lifestyle Intervention in Moderate to Severe Plaque Psoriasis and Concomitant Metabolic Syndrome: Rationale and Methodology of the METABOLyx Randomized Controlled Clinical Trial. Nutrients, 2021, 13, 3015.	4.1	7
18	The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. Journal of the American Academy of Dermatology, 2021, 85, 369-378.	1.2	46

#	Article	IF	Citations
19	Influenza Vaccination in Psoriatic Patientsâ€"Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso). Vaccines, 2021, 9, 843.	4.4	3
20	Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and Canada. Dermatology and Therapy, 2021, 11, 2159-2177.	3.0	3
21	Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern. Dermatology, 2021, 237, 759-768.	2.1	3
22	Adiponectin levels in a large pooled plaque psoriasis study population. Journal of Dermatological Treatment, 2020, 31, 531-534.	2.2	17
23	Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. Journal of Allergy and Clinical Immunology, 2020, 145, 173-182.	2.9	183
24	A 24â€week multicentre, randomized, openâ€label, parallelâ€group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderateâ€toâ€severe plaque psoriasis naive to systemic treatment. British Journal of Dermatology, 2020, 182, 869-879.	1.5	31
25	Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. Journal of Dermatological Treatment, 2020, 31, 769-775.	2.2	31
26	Guselkumab is superior to fumaric acid esters in patients with moderateâ€toâ€severe plaque psoriasis who are naive to systemic treatment: results from a randomized, activeâ€comparatorâ€controlled phase IIIb trial (POLARIS). British Journal of Dermatology, 2020, 183, 265-275.	1.5	24
27	Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 533-541.	2.4	47
28	Management of Paediatric Psoriasis by Paediatricians: A Questionnaire-Based Survey. Dermatology and Therapy, 2020, 10, 671-680.	3.0	4
29	Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors. Dermatology and Therapy, 2020, 10, 721-734.	3.0	12
30	Correct performance of subcutaneous injections in plaque psoriasis: comparison of trained and untrained patients with different application systems in routine clinical care. Journal of Dermatological Treatment, 2020, 32, 1-9.	2.2	0
31	Efficacy and safety of ixekizumab in a phase <scp>III</scp> , randomized, doubleâ€blind, placeboâ€controlled study in paediatric patients with moderateâ€toâ€severe plaque psoriasis () Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	7
32	ERAPSO: Revealing the High Burden of Obesity in German Psoriasis Patients. Dermatology and Therapy, 2019, 9, 579-587.	3.0	11
33	Interleukinâ€17 receptor <scp>A</scp> blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases. Journal of Dermatology, 2019, 46, 426-430.	1.2	15
34	Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. Journal of Investigative Dermatology, 2019, 139, 1054-1062.	0.7	150
35	Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature. Clinical, Cosmetic and Investigational Dermatology, 2018, Volume 11, 451-459.	1.8	10
36	Development and validation of the International Hidradenitis Suppurativa Severity Score System () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Dermatology, 2017, 177, 1401-1409.	1.5	301

#	Article	IF	Citations
37	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1Âyear: Results from the CLEAR study. Journal of the American Academy of Dermatology, 2017, 76, 60-69.e9.	1.2	258
38	Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial <scp>VEGFR</scp>â€2 protein halfâ€life in part via a <scp>VE</scp>â€cadherinâ€dependent mechanism. Experimental Dermatology, 2017, 26, 194-201.	2.9	32
39	Dimethylfumarate effectively inhibits lymphangiogenesis via p21 induction and G1 cell cycle arrest. Experimental Dermatology, 2016, 25, 200-205.	2.9	12
40	The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer, 2016, 16, 763.	2.6	33
41	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. Journal of the American Academy of Dermatology, 2015, 73, 400-409.	1.2	472